India offers incentives to domestic drugmakers for APIs; After PhIII trials, Taiho licenses Arokaris in Japan
India has been dependent on the import of active pharmaceutical ingredients to manufacture its drugs. But thanks to a a recent government initiative, 35 of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.